CompanyGraph
Sells DNA sequencing machines that only work with the company's own reagents and flow cells, creating repeat purchases for life.
- Depends onUpstream position: supplies 5 industries, depends on 0
- ScaleMarket cap is higher than 95% of all stocks globally
- FinancialsAltman Z-Score: safe zone
- Interpretations3 currently firing — 1 · 2
What this company is and how it runs — written from structure, not news.
Illumina sells DNA sequencing machines to hospitals and research labs, but the real business is the reagent kits and flow cells that each machine consumes for its entire working life. The instrument's optical sensors are calibrated to detect the specific light emitted by Illumina's own fluorescent nucleotides, so switching to a competitor's reagents changes the emission wavelengths and breaks detection — and because each platform like the NovaSeq or MiSeq uses its own flow cell geometry, consumables cannot even be swapped between Illumina's own machines, let alone sourced from outside. Any clinical lab that has already validated a diagnostic test on one of these instruments — prenatal screening, for instance — must run six to twelve months of regulatory revalidation before it can legally move to a different platform, which means the switching cost is not just technical but bureaucratic. The single point of fragility in all of this is the flow cell: each one requires photolithographic patterning inside semiconductor-grade cleanrooms in San Diego and Singapore, and if a contamination event or a problem with the patterning equipment sends a bad reagent lot into the field, sequencing failures ripple across every instrument running that lot simultaneously, and fixing it means requalifying the entire matched system from scratch.
How does this company make money?
When a lab first buys an instrument — a NovaSeq, MiSeq, or NextSeq — the company collects a one-time payment for that capital equipment. From that point on, every sequencing experiment the lab runs consumes a reagent kit and a flow cell, both of which must be repurchased each time. Those per-run sales continue for as long as the instrument is in use. The company also sells service contracts that cover instrument maintenance and software updates.
What makes this company hard to replace?
A clinical lab that has validated a diagnostic test — such as a prenatal screening test — on one sequencing platform must run a full revalidation study, lasting 6 to 12 months, before it can legally use a different platform for that test. Beyond the regulatory hurdle, the software pipelines labs use to analyze sequencing data are calibrated to the specific error patterns and quality signals of the platform they were built on, and those calibrations do not transfer to a different technology. Lab staff also require platform-specific training on how to handle reagents and run quality checks, adding further cost and time to any switch.
What limits this company?
Every flow cell has to be individually patterned using ASML photolithography equipment inside semiconductor-grade cleanrooms in San Diego and Singapore. That patterning step cannot simply be sped up by adding more workers — it is constrained by the physical capacity of those cleanrooms. The total number of DNA sequencing runs that labs around the world can perform is ultimately capped by how many flow cells those two facilities can produce.
What does this company depend on?
The company cannot operate without ASML photolithography equipment to pattern flow cells, fluorescent nucleotide analogs built around its proprietary reversible terminator chemistry, CCD imaging sensors calibrated to specific fluorophore wavelengths, semiconductor-grade cleanroom facilities in San Diego and Singapore, and FDA 510(k) clearances that allow its instruments to be used in clinical diagnostic settings.
Who depends on this company?
Clinical laboratories running NIPT programs — prenatal tests that screen for chromosomal conditions — would lose their screening capacity if sequencing reagents became unavailable. Pharmaceutical companies conducting genomic clinical trials would face delays to their research protocols if the sequencing platforms went offline. Population genomics projects like UK Biobank, which sequences hundreds of thousands of people's genomes to study disease, would lose the ability to process new samples without compatible sequencing chemistry.
How does this company scale?
Once a reagent kit formulation is established, producing more kits is relatively straightforward — automated liquid handling and packaging lines can run at high volume without much added complexity. Flow cells are the hard part: each one requires individual photolithographic patterning and surface chemistry treatment inside the cleanrooms in San Diego and Singapore, and that process cannot be meaningfully accelerated beyond the physical limits of those facilities. Reagent revenue can grow quickly; flow cell production cannot keep pace at the same rate.
What external forces can significantly affect this company?
CFIUS, the US government body that reviews foreign investments for national security risks, can block acquisitions or technology transfers involving genomics companies because DNA sequencing has potential military and intelligence applications. European GDPR rules and emerging genetic privacy laws in other countries restrict how genomic data can be moved across borders, limiting the company's ability to support large international sequencing projects. Disruptions to semiconductor supply chains, particularly those involving Taiwan, can affect the availability of CCD sensors that the optical detection systems rely on.
Where is this company structurally vulnerable?
If the reversible terminator chemistry or the flow cell surface preparation drifts out of specification — through a contamination event, a formulation error, or a failure of the ASML photolithography equipment used to pattern the flow cells — sequencing errors would spread across every instrument in the field running that batch of reagents. Because all three components are so tightly matched, fixing the problem means requalifying the entire system from scratch, not just replacing one part. During that period, clinical labs running prenatal screening programs and pharmaceutical companies running genomic trials could not simply switch to another platform without triggering the same 6 to 12 month revalidation process.
Price is read as structure — trend, levels, range, peak and volatility drawn on the chart. It does not predict where price goes next.
Sign in to view price data.
Sign in1 interpretation currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsHow is this stock behaving?
Close In Upper Portion Of Recent Range, Bollinger Bands, And RSI
Current close sits in the upper portion of the 14-week high-low range; current close sits in the upper portion of its 20-week Bollinger Bands; RSI sits above its 20-week recent mean (Bollinger %B applied to RSI).
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
The reported statements, read against the company's own industry.
2 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsHow does this company use capital?
Cumulative Treasury Stock Significant With Elevated ROE And FCF-To-Equity
Three observations have aligned: the cumulative treasury-stock balance is significant relative to current equity, return on equity sits in the upper industry-benchmarked peer range, and free cash flow as a share of equity book value is in the upper portion of its mapped range.
Industry-Benchmarked Return on Capital Elevated
Three industry-benchmarked observations co-occur: return on equity is elevated, asset turnover is elevated, and return on assets is elevated. Because asset turnover and ROA both fire alongside ROE, the elevated ROE is not solely a leverage effect.
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Financial Health
Supply Chain
Scale
Companies that share the same coordination system — how they create, deliver, or capture value.
Companies that share active interpretations — structural patterns currently present in both stocks.